Kinetic Patterns of Antibiotic Consumption in German Acute Care Hospitals from 2017 to 2023
Authors:
- Birgitta SchweickertBSBirgitta Schweickert
- Niklas WillrichNWNiklas Willrich
- Marcel FeigMFMarcel Feig
- Marc SchneiderMSMarc Schneider
- Michael BehnkeMBMichael Behnke
- Luis Alberto Peña DiazLDLuis Alberto Peña Diaz
- Christine GeffersCGChristine Geffers
- Imke WietersIWImke Wieters
- Karin GröschnerKGKarin Gröschner
- Doreen RichterDRDoreen Richter
- Alexandra HoffmannAHAlexandra Hoffmann
- Tim EckmannsTETim Eckmanns
Open Access
- 18 March 2025
- journal article
- research article
- Published by MDPI AG in Antibiotics
- Vol. 14 (3) , 316
Abstract
Background: Antimicrobial consumption (AMC) patterns, besides prescribing behaviors, reflect the changing epidemiology of infectious diseases. Routine surveillance data have been used to investigate the development of AMC from 2017 to 2023 and the impact of COVID-19 within the context of the framing time periods. Methods: Data from 112 hospitals, continuously participating from 2017 to 2023 in the national surveillance system of hospital antimicrobial consumption based at the Robert Koch Institute, were analyzed according to the WHO ATC (Anatomical Therapeutic Chemical)/DDD (Defined Daily Dose) method and categorized according to the WHO AWaRe-classification. AMC was quantified by consumption density (CD) expressed in DDD/100 patient days (PD) and DDD/100 admissions (AD). The time period was subdivided into three phases: pre-pandemic phase (2017–2019), main pandemic phase (2020–2021) and transition phase (2022–2023). Linear regression models have been used to determine the presence of an overall trend, the change in intra-phasic trends and phase-specific mean consumption levels over time. Results: From 2017 to 2023 total antibiotic consumption decreased by 7% from 57.1 to 52.9 DDD/100 PD. Four main kinetic patterns emerged across different antibiotic classes: Pattern 1 displays a decreasing pre-pandemic trend, which slowed down throughout the pandemic and transition phase and was exhibited by second-generation cephalosporins and fluoroquinolones. Pattern 2 reveals a rising pre-pandemic trend, which decelerated in the pandemic phase and accelerated again in the transition phase and was expressed by aminopenicillins/beta-lactamase inhibitors, beta-lactamase sensitive pencillins, azithromycin and first-generation cephalosporins. Pattern 3 shows elevated mean consumption levels in the pandemic phase exhibited by carbapenems, glycopeptides, linezolid and third-generation cephalosporins. Pattern 4 reveals a rising trend throughout the pre-pandemic and pandemic phase, which reversed in the transition phase without achieving pre-pandemic levels and was expressed by beta-lactamase resistant penicillins, daptomycin, fosfomycin (parenteral) and ceftazidime/avibactam. Conclusions: Kinetic consumption patterns across different antibiotic classes might reflect COVID-19-related effects and associated changes in the epidemiology of co-circulating pathogens and health care supply. Broad-spectrum antibiotics with persisting elevated consumption levels throughout the transition phase require special attention and focused antimicrobial stewardship activities.Keywords
This publication has 53 references indexed in Scilit:
- WHO's essential medicines and AWaRe: recommendations on first- and second-choice antibiotics for empiric treatment of clinical infectionsClinical Microbiology and Infection, 2024
- Krankenhaus-Report 20242024
- Increasing numbers and complexity of Staphylococcus aureus bloodstream infection—14 years of prospective evaluation at a German tertiary care centre with multi-centre validation of findingsClinical Microbiology and Infection, 2023
- Impact of 2020 EUCAST criteria on meropenem prescription for the treatment of Pseudomonas aeruginosa infections: an observational study in a university hospitalClinical Microbiology and Infection, 2022
- Predictors and microbiology of respiratory and bloodstream bacterial infection in patients with COVID-19: living rapid review update and meta-regressionClinical Microbiology and Infection, 2021
- Evaluation of a multiplex PCR screening approach to identify community-acquired bacterial co-infections in COVID-19: a multicenter prospective cohort study of the German competence network of community-acquired pneumonia (CAPNETZ)Infection, 2021
- Antibiotic prescribing in patients with COVID-19: rapid review and meta-analysisClinical Microbiology and Infection, 2021
- Stationäre und intensivmedizinische Versorgungsstrukturen von COVID-19-Patienten bis Juli 2020Medizinische Klinik - Intensivmedizin und Notfallmedizin, 2021
- Bacterial co-infection and secondary infection in patients with COVID-19: a living rapid review and meta-analysisClinical Microbiology and Infection, 2020
- New EUCAST definitions of S, I and R from 2019 – German physicians are largely not aware of the changesInfection, 2020